Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma

NCT03139331 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03139331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03139331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Completed
Start date
June 6, 2017
Completion date
September 30, 2020
Enrollment
16 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

refractory sarcoma, sarcoma